NCT06533579View on ClinicalTrials.gov

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2031

Conditions
B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMarginal Zone LymphomaFollicular LymphomaMantle Cell LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaBurkitt LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Non Hodgkin LymphomaMixed Phenotype Acute Leukemia
Interventions
GENETIC

Dose Level 1, VNX-101

Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion

GENETIC

Dose Level 2, VNX-101

Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion

GENETIC

Dose Level 3, VNX-101

Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion

GENETIC

Dose Level 4, VNX-101

Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion

Trial Locations (8)

10595

RECRUITING

New York Medical College, Valhalla

27599

RECRUITING

University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill

37203

RECRUITING

TriStar BMT, Nashville

43210

RECRUITING

The Ohio State University Wexner Medical Center, Columbus

45242

RECRUITING

Oncology Hematology Care, Cincinnati

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

91010

RECRUITING

City of Hope, Duarte

All Listed Sponsors
lead

Vironexis Biotherapeutics Inc.

INDUSTRY